Zobrazeno 1 - 10
of 117
pro vyhledávání: '"Panwen Tian"'
Impact of non-canonical ALK fusion on the efficacy of targeted therapy in non-small cell lung cancer
Autor:
Hao Zeng, Qi Wei, Yuan Tang, Yuanyuan Zhang, Sihan Tan, Qin Huang, Xin Pu, Yalun Li, Panwen Tian, Ting Gao, Xiuyuan Hao
Publikováno v:
Chinese Medical Journal, Vol 137, Iss 12, Pp 1468-1470 (2024)
Externí odkaz:
https://doaj.org/article/1d1349ed388a427aa7810f23bb9d5f66
Autor:
Qi Wei, Taibing Deng, Junhua Wu, Hao Zeng, Chang Qi, Sihan Tan, Yuanyuan Zhang, Qin Huang, Xin Pu, Weiguo Xu, Weimin Li, Panwen Tian, Yalun Li
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-9 (2024)
Abstract Background Immune checkpoint inhibitors (ICI) combined with chemotherapy are efficacious for treating advanced non-small cell lung cancer (NSCLC); however, the effectiveness of this approach in the malignant pleural effusion (MPE) population
Externí odkaz:
https://doaj.org/article/d82f8a98c34442ff8e883bac55ae42cb
Publikováno v:
Chinese Journal of Lung Cancer, Vol 27, Iss 2, Pp 138-146 (2024)
In recent years, there has been a consensus regarding the enhancement of prognosis in patients with advanced non-small cell lung cancer (NSCLC) through the utilization of immune checkpoint inhibitors (ICIs). Numerous clinical studies have also demons
Externí odkaz:
https://doaj.org/article/9314fb521697496b847cb91efbd384c8
Publikováno v:
BMC Pulmonary Medicine, Vol 24, Iss 1, Pp 1-11 (2024)
Abstract Background Several studies have indicated that intrapleural infusion of bevacizumab is an effective treatment for non-small cell lung cancer (NSCLC) with malignant pleural effusion (MPE). However, the impact of bevacizumab administered throu
Externí odkaz:
https://doaj.org/article/f049201c388847638763aa59185e6bf9
Autor:
Gen Lin, Zhijie Wang, Qian Chu, Yi Hu, Dingzhi Huang, Jun Wang, Fan Yang, Wenzhao Zhong, Chengzhi Zhou, Bo Zhu, Xinghao Ai, Baoshan Cao, Yabing Cao, Mingqiu Chen, Xiaohui Chen, Tianqing Chu, Jianchun Duan, Yun Fan, Yong Fang, Shuitu Feng, Weineng Feng, Hui Guo, Chengbo Han, Yong He, Shaodong Hong, Jie Hu, Meijuan Huang, Yan Huang, Da Jiang, Kan Jiang, Richeng Jiang, Bo Jin, Shi Jin, Jisheng Li, Min Li, Ziming Li, Chao Li, Jie Lin, Anwen Liu, Si‐Yang Maggie Liu, Liu Yutao, Zhefeng Liu, Zhe Liu, Zhenhua Liu, Zhentian Liu, Zhigang Liu, Yuping Lu, Tangfeng Lv, Zhiyong Ma, Qian Miao, Min Peng, Xingxiang Pu, Xiu Bao Ren, Jianzhen Shan, Jinlu Shan, Peng Shen, Bo Shen, Meiqi Shi, Yong Song, Zhengbo Song, ChunXia Su, Jianguo Sun, Panwen Tian, Jinliang Wang, Feng Wang, Huijuan Wang, Jialei Wang, Qian Wang, Wenxian Wang, Yan Wang, Lin Wu, Fang Wu, Yang Xia, Congying Xie, Conghua Xie, Tao Xin, Jianping Xiong, Haipeng Xu, Song Xu, Yiquan Xu, Bin Xu, Chunwei Xu, Xiaolong Yan, Zhenzhou Yang, Wenxiu Yao, Yao Yu, Ye Feng, Zongyang Yu, Yongfeng Yu, Dongsheng Yue, Haibo Zhang, HongMei Zhang, Li Zhang, Longfeng Zhang, Qiuyu Zhang, Tongmei Zhang, Bicheng Zhang, Jun Zhao, Mingfang Zhao, Xiaobin Zheng, Qiaofeng Zhong, Jin Zhou, Penghui Zhou, Zhengfei Zhu, Juntao Zou, Zihua Zou
Publikováno v:
Thoracic Cancer, Vol 15, Iss 5, Pp 419-426 (2024)
Abstract Immune checkpoint inhibitor (ICI) rechallenge in non‐small cell lung cancer (NSCLC) is a promising therapeutic strategy. The situation for ICI rechallenge can be divided into three categories: adverse events (AEs); resistance to ICIs, and
Externí odkaz:
https://doaj.org/article/5593cfcf22cf4de189ad661dbe843899
Autor:
Yalun Li, Liyan Ji, Yingqian Zhang, Jiexin Zhang, Alexandre Reuben, Hao Zeng, Qin Huang, Qi Wei, Sihan Tan, Xuefeng Xia, Weimin Li, Jianjun Zhang, Panwen Tian
Publikováno v:
MedComm, Vol 5, Iss 6, Pp n/a-n/a (2024)
Abstract Tumor mutational burden (TMB) and T‐cell receptor (TCR) might predict the response to immunotherapy in patients with non–small cell lung cancer (NSCLC). However, the predictive value of the combination of TMB and TCR was not clear. Targe
Externí odkaz:
https://doaj.org/article/5b88ca7b94804c7898390563f206f409
Autor:
Dingzhi Huang, Gen Lin, Qian Chu, Yi Hu, Jun Wang, Zhijie Wang, Fan Yang, Wenzhao Zhong, Chengzhi Zhou, Bo Zhu, Xinghao Ai, Baoshan Cao, Yabing Cao, Mingqiu Chen, Xiaohui Chen, Tianqing Chu, Jianchun Duan, Yun Fan, Yong Fang, Shuitu Feng, Weineng Feng, Hui Guo, Chengbo Han, Yong He, Shaodong Hong, Jie Hu, Meijuan Huang, Yan Huang, Da Jiang, Kan Jiang, Richeng Jiang, Bo Jin, Shi Jin, Jisheng Li, Min Li, Ziming Li, Chao Li, Jie Lin, Anwen Liu, Si‐Yang Maggie Liu, Yutao Liu, Zhefeng Liu, Zhe Liu, Zhenhua Liu, Zhentian Liu, Zhigang Liu, Yuping Lu, Tangfeng Lv, Zhiyong Ma, Qian Miao, Min Peng, Xingxiang Pu, Xiu Bao Ren, Jianzhen Shan, Jinlu Shan, Peng Shen, Bo Shen, Meiqi Shi, Yong Song, Zhengbo Song, ChunXia Su, Jianguo Sun, Panwen Tian, Jinliang Wang, Feng Wang, Huijuan Wang, Jialei Wang, Qian Wang, Wenxian Wang, Yan Wang, Lin Wu, Fang Wu, Yang Xia, Congying Xie, Conghua Xie, Tao Xin, Jianping Xiong, Haipeng Xu, Song Xu, Yiquan Xu, Bin Xu, Chunwei Xu, Xiaolong Yan, Zhenzhou Yang, Wenxiu Yao, Yao Yu, Ye Feng, Zongyang Yu, Yongfeng Yu, Dongsheng Yue, Haibo Zhang, HongMei Zhang, Li Zhang, Longfeng Zhang, Qiuyu Zhang, Tongmei Zhang, Bicheng Zhang, Jun Zhao, Mingfang Zhao, Xiaobin Zheng, Fengqiao Zhong, Jin Zhou, Penghui Zhou, Zhengfei Zhu, Juntao Zou, Zihua Zou
Publikováno v:
Thoracic Cancer, Vol 14, Iss 34, Pp 3421-3429 (2023)
Abstract Immune checkpoint inhibitors (PD‐1/PD‐L1 and CTLA‐4 blockade) have revolutionized the treatment landscape in non‐small cell lung cancer (NSCLC). Secondary resistance to immunotherapy (IO), which poses a substantial challenge in clini
Externí odkaz:
https://doaj.org/article/bdd49d5369d24d70bad9a053f8310938
Publikováno v:
The Clinical Respiratory Journal, Vol 17, Iss 11, Pp 1158-1168 (2023)
Abstract Background Patients with malignant pleural effusion (MPE) typically have poor prognoses, and predicting survival is challenging. The present study aimed to identify prognostic factors of overall survival (OS) in non‐small cell lung cancer
Externí odkaz:
https://doaj.org/article/0a04b13754a74722bd7f04aec8ca2539
Autor:
Pingli Wang, Liming Cao, Panwen Tian, Shengxiang Ren, Liyun Miao, Chengzhi Zhou, Yun Fan, Yuping Li, Dongqing Lv, Xin Zhao, Mei Yang, Chaonan Zhu, Bing Yu, June Xu, Yong Song, Kai Wang
Publikováno v:
Cancer Communications, Vol 43, Iss 9, Pp 1059-1063 (2023)
Externí odkaz:
https://doaj.org/article/39fceaab02494d4db904bd9cf47c9890
Publikováno v:
Chinese Journal of Lung Cancer, Vol 26, Iss 8, Pp 605-614 (2023)
Background and objective Immune checkpoint inhibitors (ICIs) therapy lacks viable biomarkers for response and prognosis prediction. This study aimed to investigate the correlation of peripheral blood laboratory test results combined with lymphocyte s
Externí odkaz:
https://doaj.org/article/e2e519e5e60e49f7b79ba2d6e468416d